AffirmedRx’s Efforts to Address PBM Transparency and Drive Industry Change
Greg Baker, CEO of AffirmedRx, shared with MHE editors how the company is addressing ongoing challenges in the pharmacy benefit management (PBM) industry, particularly corporate consolidation and transparency issues.
Greg Baker, CEO of AffirmedRx, shared with MHE editors how the company is addressing ongoing challenges in the pharmacy benefit management (PBM) industry, particularly corporate consolidation and transparency issues.
Baker noted the difficulty of resolving these problems solely through legislation due to loopholes and challenges in large, integrated companies.
“It’s going to be really hard to legislate our way out of it without having that law of unintended consequences,” he said.
AffirmedRx has been engaging policymakers, with Baker and his team making over 60 trips in the last two years to Washington, D.C., to educate federal agencies about PBM practices.
He highlighted that competition is also difficult because larger PBMs often keep savings for themselves instead of providing them to clients, which inflates profits instead of reducing costs.
Litigation could drive the most change, he suggested, as high-profile lawsuits, such as those involving Johnson & Johnson and Wells Fargo, are capturing employers' and benefit leaders' attention, which potentially sparks a shift toward better practices.
FDA Approves Amvuttra for ATTR-CM in Extended Label
March 21st 2025This expanded indication for Amvuttra makes it the first and only FDA-approved treatment for transthyretin amyloidosis with cardiomyopathy (ATTR-CM) and the polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR-PN) in adults.
Read More
Breaking Down Health Plans, HSAs, AI With Paul Fronstin of EBRI
November 19th 2024Featured in this latest episode of Tuning In to the C-Suite podcast is Paul Fronstin, director of health benefits research at EBRI, who shed light on the evolving landscape of health benefits with editors of Managed Healthcare Executive.
Listen
In this latest episode of Tuning In to the C-Suite podcast, Briana Contreras, an editor with MHE had the pleasure of meeting Loren McCaghy, director of consulting, health and consumer engagement and product insight at Accenture, to discuss the organization's latest report on U.S. consumers switching healthcare providers and insurance payers.
Listen
FDA Approves First-Ever Cell Therapy Treatment for Rare Progressive Eye Disease
March 20th 2025Encelto is small, semi-permeable capsule implanted in the eye that contains allogeneic retinal pigment epithelium cells genetically engineered to produce specific therapeutic proteins. It will be available in June 2025.
Read More
